CCP Quality and Safety Practices 2

Question 1

A consultant pharmacist performing a medication use evaluation (MUE) finds that 40% of residents on warfarin lack documented INR monitoring within the past 30 days. What is the MOST appropriate immediate action?

Accepted Answer

Present findings to the quality assurance committee and develop a corrective action plan

Answer

MUE findings must be reported to the QA committee, which then implements corrective action plans to address the monitoring gap.

Question 2

Which of the following best describes the purpose of a root cause analysis (RCA) in a long-term care pharmacy setting?

Accepted Answer

To identify systemic factors contributing to an adverse event and prevent recurrence

Answer

RCA is a non-punitive, systems-based process that identifies contributing factors to prevent future similar events.

Question 3

Under USP <797>, which beyond-use dating (BUD) category applies to a sterile compounded preparation made from non-sterile components under Category 1 conditions?

Accepted Answer

12 hours at controlled room temperature

Answer

USP <797> Category 1 CSPs made from non-sterile components have a BUD of 12 hours at room temperature or 24 hours refrigerated.

Question 4

A facility's fall-with-injury rate has risen 25% after adding a new CNS medication to the formulary. Which quality tool is MOST appropriate to identify contributing factors?

Accepted Answer

Fishbone (Ishikawa) diagram

Answer

A fishbone diagram systematically maps potential cause categories (medication, environment, staff, process) contributing to an adverse outcome.

Question 5

When conducting a prospective drug regimen review in a skilled nursing facility, the consultant pharmacist identifies a resident taking both a benzodiazepine and an opioid. According to CMS guidelines, what is required?

Accepted Answer

Documentation of the clinical rationale and a gradual dose reduction plan unless contraindicated

Answer

CMS F-tag guidance requires documented clinical justification and a gradual dose reduction plan for concurrent benzodiazepine-opioid use unless clinically contraindicated.

(CCP) Certified Consultant Pharmacist Practice Test

(CCP) Certified Consultant Pharmacist Practice Test

CCP Quality and Safety Practices 2